Issue: 2013 > July/August > original article

Routine duodenal biopsy to screen for coeliac disease is not effective



ORIGINAL ARTICLE
J.P.W. Burger, J.W.R Meijer, P.J. Wahab
AbstractPDF

Abstract

Background: Routine duodenal biopsies during upper
gastrointestinal endoscopy (UGE) have been suggested
to be useful in detecting coeliac disease (CD). However
results from previous studies are not conclusive. The
aim of this study is to investigate the diagnostic yield and
cost-effectiveness of routine duodenal biopsy during UGE.
Methods: In this retrospective single-centre study, we
studied 6442 patients undergoing first-time UGE at the Rijnstate Hospital, Arnhem, the Netherlands, from January 2009 to December 2010. All UGE reports were analysed for indication, duodenal intubation, and endoscopic aspect of duodenal mucosa. Endomysium and
tissue transglutaminase antibody titre, when present, were
scored as positive or negative. CD was defined as Marsh
3a or higher. Costs of duodenal biopsies and pathology
analysis were calculated. Comparisons were done with
T-tests for continuous data and Chi-square tests for categorical data. Results: Forty-one patients had newly diagnosed CD; 34 of these 41 patients had definite indications for biopsy prior to UGE, e.g. positive serology or symptoms. Thus, routine duodenal biopsies identified seven patients as having CD, who otherwise would not have been biopsied. The number needed to biopsy was therefore 577, spending more than v 30,000 per case.
Conclusions: We do not recommend routine duodenal
biopsy to screen for coeliac disease because of the high
number needed to biopsy as well as high costs.